Welcome to Altum sequencing
“Residual cells after therapy are the main cause of cancer progression and relapse”
The quantification of cancer cells remaining after treatment (Minimal Residual Disease, MRD) is a powerful tool to define the level of response and clinical outcome of cancer patients.
Altum is a biomedical company specializing in the identification of patient specific genetic markers suitable for MRD monitoring.
Full-service genetic lab for clinical research
Altum Sequencing offers its services to the pharma industry to develop genetic characterization of patients enrolled in clinical trials, from baseline genetic screening to NGS based MRD testing and definition of resistance related alterations.
Our services include analysis of diagnosis / baseline samples to identify genetic alterations related with progression, drug response and clinical outcome. From these genetic alterations we select the best markers to be tracked in follow-up samples (MRD).
We have validated our proprietary MRD analysis in several proliferative diseases including: